+1 Recommend
1 collections
      Call for Papers in Kidney and Blood Pressure ResearchKidney Function and Omics Science

      Submission Deadline: December 20, 2023

      Submit now

      • Record: found
      • Abstract: found
      • Article: found

      Effect of Intraperitoneal Administration of Low-Molecular-Weight Heparin on Plasma Tissue Factor Pathway Inhibitor Levels in CAPD Patients


      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          We investigated the systemic effect of intraperitoneal low-molecular-weight heparin (LMWH) in continuous ambulatory peritoneal dialysis (CAPD) patients by measuring plasma total tissue factor pathway inhibitor (TFPI) levels, regarding the fact that the levels of plasma TFPI increases 2- to 4-fold after subcutaneous and intravenous administration of unfractioned heparin or LMWH. Eleven men and 6 women who had been on CAPD for 32 ± 26 months and 15 healthy controls were included in the study. After administration of intraperitoneal enoksiparin in dialysate, plasma samples were obtained 4 h later. TFPI levels were significantly higher in CAPD patients (207.8 ± 55 ng/ml) compared to the healthy subjects (72.5 ± 29 ng/ml) (p < 0.0001). Both TFPI levels (225.9 ± 47 vs. 207.8 ± 55 ng/ml) (p < 0.54) and plasma factor Xa (anti-FXa assay) (0.097 ± 0.14 vs. 0.093 ± 0.16 U/ml) (p < 0.54) levels did not show any statistical difference before and after intraperitoneal administration of LMWH. By these findings we might suggest that intraperitoneal LMWH does not have any systemic effect.

          Related collections

          Author and article information

          S. Karger AG
          May 2002
          02 May 2002
          : 91
          : 1
          : 162-163
          aDokuz Eylul University School of Medicine, Department of Medicine, Division of Hematology/Oncology, and bDivision of Nephrology, Izmir, Turkey
          57620 Nephron 2002;91:162–163
          © 2002 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 1, References: 5, Pages: 2
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/57620
          Self URI (text/html): https://www.karger.com/Article/FullText/57620
          Self URI (journal page): https://www.karger.com/SubjectArea/Nephrology
          Short Communication

          Cardiovascular Medicine,Nephrology
          Continuous ambulatory peritoneal dialysis,Tissue factor pathway inhibitor,Intraperitoneal low-molecular-weight heparin


          Comment on this article